SNIPR Biome raises €35M Series B to advance CRISPR Therapies for Antimicrobial Resistance
SNIPR Biome, a Copenhagen-based clinical-stage biotech developing CRISPR-based microbial gene therapies, has secured €35 million in a Series B round.

The best Articles in our Network